“The study evaluated participants from the ECLAT study,” writes Farsalinos. “A randomized study which assessed the efficacy of e-cigarettes as a smoking cessation product.” The research looked at users of high, low, and zero nicotine products and then classified participants as quitters, reducers (around 50 % reduction in smoking consumption) and failures (less than 50 % to no reduction in smoking consumption).
The team noted that smoking causes an immediate elevation of blood pressure and heart rate although “epidemiological studies show that smoking cessation may be associated with an elevated risk for future development of hypertension as well.” It is clear that a quit method overcoming this problem would offer a huge health dividend.
The team measured blood pressure at the beginning and over the 52-week period to assess any potential changes in relation to the smoking status. The product used was a three-piece cigalike utilizing disposable cartridges.
The majority of subjects had normal blood pressure readings at the outset and therefore displayed no change during the study. But for those presenting high blood pressure at the outset: “we observed a statistically significant reduction in systolic blood pressure in those with continuous reduction in smoking consumption and in those who had quit smoking with the use of e-cigarettes.”
“Of note, the reduction in blood pressure was evident even after adjusting for confounders such as age, gender and weight gain. Both smoking reduction and abstinence were associated with blood pressure reductions, with stronger association observed in those with smoking abstinence.”
“This is yet another clinical study,” Farsalinos writes, “showing that we expect improvements in the health status of smokers who switch to e-cigarettes. I should note that although I am the first author of this study, all credit should go to Professor Polosa and his team who did an excellent job conducting the ECLAT study and generating such important data.”